Overview

A Clinical Study To Understand How Radiolabeled MK-5475 Is Taken Up By The Body, Broken Down And Then Removed From The Body in Healthy Participants (MK-5475-011)

Status:
COMPLETED
Trial end date:
2022-10-25
Target enrollment:
Participant gender:
Summary
The goal of this study is to understand how radiolabeled MK-5475 administered intravenously (IV) is taken up by the body, broken down and then removed from the body in healthy male participants. The study also aims to understand how much of the compound is broken down and how much leaves the body unchanged.
Phase:
PHASE1
Details
Lead Sponsor:
Merck Sharp & Dohme LLC